{'fraction_non_alphanumeric': 0.02491103202846975, 'fraction_numerical': 0.013048635824436536, 'mean_word_length': 6.092436974789916, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Potential Warfarin‐Ciprofloxacin Interaction in Patients Receiving Long‐Term Anticoagulation

This study prospectively evaluated the potential interaction between the oral anticoagulant warfarin and the quinolone antimicrobial agent ciprofloxacin. After a 10‐day placebo lead‐in phase, 16 patients stabilized with long‐term warfarin therapy were randomized to receive ciprofloxacin 500 mg or a matching placebo twice/day for 10 days. International normalized ratios (INRs) measured by both standard laboratory analysis and by Coumatrak (finger‐stick) methods were evaluated at 3‐ to 5‐day intervals. No patient experienced a significant increase in INR. No patient experienced a bleeding event. These data support the fact that a warfarin‐ciprofloxacin interaction does not routinely occur at this dosage and duration of ciprofloxacin therapy.